- Aspirin showed no overall cancer prevention effect in 9,350 older adults in ASPREE.
- Subgroups: Benefit seen in older, nonsmoking, lower BMI patients with family history of cancer or CHIP ≥10% VAF.
- Predictors: CHIP = strongest predictor of benefit; Smoking = strongest predictor of harm
- Tailored use improved 5-year cancer risk reduction by ~2% vs treating all.
- Mostly healthy, White Australian cohort; aspirin started only at ≥70; some biospecimens collected after diagnosis; nonprespecified analysis.
Source: JAMA Oncology
